Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06903065 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Final enrollment: 56 participants (planned 50) Primary completion date changed from estimate of Sep 30, 2026 to Sep 24, 2026 · Completion date: Dec 30, 2026 to Dec 3, 2026 Show 2 more changesShow less
    • Primary completion date changed from estimate of Sep 30, 2026 to Sep 24, 2026
    • Completion date: Dec 30, 2026 to Dec 3, 2026
  2. Eligibility criteria shortened, about 19 words
  3. Site details revised at 1 of 15 sitesv13
  4. Primary completion moved earlier from Dec 30, 2026 to Sep 30, 2026v12
  5. Trial sites reduced: 24 → 15 locationsv11
Show 9 earlier versionsHide 9 earlier versions
  1. Study sites: 25 to 24v10
  2. Trial status: Recruiting to Active, Not Recruiting Study sites: 23 to 25 · Primary and study completion dates: Sep 30, 2026 to Dec 30, 2026v9 Show 2 more changesShow less
    • Study sites: 23 to 25
    • Primary and study completion dates: Sep 30, 2026 to Dec 30, 2026
  3. Re-verified, no change to tracked fieldsv8
  4. Study sites: 22 to 23v7
  5. Study sites: 16 to 22v6
  6. Study sites: 15 to 16v5
  7. Study sites: 14 to 15v4
  8. Study sites: 7 to 14v3
  9. Study sites: 3 to 7 Start date changed from estimate of Apr 11, 2025 to Apr 14, 2025v2 Show 1 more changeShow less
    • Start date changed from estimate of Apr 11, 2025 to Apr 14, 2025
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Roche/Genentech
366 trials monitored
See 33 trials at risk
NASH / MASH
654 trials monitored
See 22 trials at risk
The purpose of this study is to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and activity of RO7790121 in participants with advanced metabolic dysfunction-associated steatohepatitis (MASH) fibrosis.
Trial Details
NCT Number NCT06903065
Lead Sponsor Hoffmann-La Roche
Conditions MASH
Enrollment 56 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov